1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

Thumbnail for A Real-World Pharmacovigilance Study of Rituximab in Two Heart Failure Phenotypes: Heart Failure With Preserved Ejection Fraction (HFpEF) and Heart Failure With Reduced Ejection Fraction (HFrEF).

ABCL - 735

A Real-World Pharmacovigilance Study of Rituximab in Two Heart Failure Phenotypes: Heart Failure With Preserved Ejection Fraction (HFpEF) and Heart Failure With Reduced Ejection Fraction (HFrEF).

Renusri Ede

Poster Presenter: Renusri Ede

$Thumbnail for Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study$

ABCL - 736

Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study

John M. Burke

Poster Presenter: John M. Burke

SOHO 2026 Annual Meeting

Posters by Session

A Real-World Pharmacovigilance Study of Rituximab in Two Heart Failure Phenotypes: Heart Failure With Preserved Ejection Fraction (HFpEF) and Heart Failure With Reduced Ejection Fraction (HFrEF).

Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study

Temporal Trends in Sepsis-Related Mortality Among Patients With Non-Hodgkin Lymphoma: A 25-Year CDC WONDER Database Analysis

A Phase 1/2, First-in-Human, Multicenter Study of DS3790, a CD37-Directed DXd Antibody-Drug Conjugate, in Patients With B-Cell Non-Hodgkin Lymphoma

Demographic and Regional Disparities in Respiratory Failure-Related Mortality Among Older Adults With Non-Hodgkin Lymphoma: A 26-Year Nationwide Analysis

Genomic Landscape of Primary Thyroid Lymphoma (Ptl): CD79B/MYD88 Alterations and Implications for Polatuzumab-Based Therapy

Vispa-cel, an Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Post-CAR-T Relapse in DLBCL: Real-World Salvage Therapy Patterns and Outcomes at a Tertiary Academic Center

Rondecabtagene Autoleucel, a Dual-Targeting CD19/CD20 CAR T-Cell Therapy, Exhibits a Manageable Safety Profile With Low Rates of Grade = 3 CRS and ICANS in Relapsed/Refractory Large B-Cell Lymphoma